Spain’s First BSL-4 Lab: Fighting Deadliest Viruses

A team of seven researchers is preparing to operate the first Biosafety Level 4 (BSL-4) laboratory in Spain, located within the GSK research and development center in Tres Cantos, Madrid. The facility, representing the highest level of biological containment, is designed to handle pathogens that cause severe or fatal diseases for which We find no known treatments or vaccines, such as Ebola or the Marburg virus.

The inauguration of the BSL-4 laboratory marks a significant advancement for Spanish scientific and technological capabilities, positioning the country alongside Germany, the United Kingdom, Sweden, Switzerland, Italy, France, and Hungary, all of which have similar facilities, according to a 2023 report by King’s College London. GSK’s investment in the laboratory totals 5.2 million euros.

The fresh laboratory will initially focus on two critical research areas: multi-drug resistant tuberculosis, which affects approximately half a million people annually with limited therapeutic options, and Crimean-Congo hemorrhagic fever, a tick-borne disease endemic in the Balkans with pandemic potential. David Barros, GSK’s Head of R&D in Global Health, stated that the facility will help position Spain at the forefront of research into diseases with pandemic potential and no current treatment options.

Access to the BSL-4 laboratory requires stringent safety protocols. Researchers must completely disrobe, shower, and don a hermetically sealed, positive-pressure suit before entering in pairs, undergoing mutual evaluation before proceeding. Restrictions include no access to food or restrooms during the maximum four-hour stay within the lab.

The Spanish government is also constructing its own BSL-4 laboratory at the Instituto Carlos III in Majadahonda, expected to be operational next year. A collaboration agreement has been established between the government and GSK, and President Pedro Sánchez visited the GSK facility on March 3rd.

Currently, there are eight institutions with BSL-4 laboratories in the European Union, and a total of 51 such facilities in 27 countries worldwide, as reported by the Global BioLabs 2023 study from King’s College London. GSK anticipates beginning operations with live pathogens in the Tres Cantos BSL-4 laboratory by late 2026 or early 2027.